GlassScriptPhysician profile
Kamal Mohan
NPI 1558361998
$893.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $113 · 2022: $40.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $324.98 | 2019 | |
| Genzyme Corporation | $160.36 | 2019 | |
| Optinose US, INC. | $113.09 | 2019 | |
| Abbvie INC. | $112.94 | 2020 | |
| Novartis Pharmaceuticals Corporation | $56.97 | 2019-2022 | |
| Alk-Abello, INC | $37.18 | 2019 | |
| Celgene Corporation | $24.32 | 2019 | |
| Shire North American Group INC | $17.21 | 2019 | |
| Kaleo, INC. | $16.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.20 | 2019 | |
| Grifols USA, LLC | $14.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.